Arrhythmias in the Heart Transplant Patient

David Hamon,¹ Jane Taleski,² Marmar Vaseghi,¹ Kalyanam Shivkumar¹ and Noel G Boyle¹

1. UCLA Cardiac Arrhythmia Center, UCLA Health System, David Geffen School of Medicine at UCLA, Los Angeles, US;

2. Department of Cardiac Electrophysiology, University Clinic of Cardiology, University of St. Cyril and Methodius, Skopje, Former Yugoslav Republic of Macedonia

Abstract

Orthotopic heart transplantation (OHT) is currently the most effective long-term therapy for patients with end-stage cardiac disease, even as left ventricular devices show markedly improved outcomes. As surgical techniques and immunosuppressive regimens have been refined, short-term mortality caused by sepsis has decreased, while morbidity caused by repeated rejection episodes and vasculopathy has increased, and is often manifested by arrhythmias. These chronic transplant complications require early and aggressive multidisciplinary treatment. Understanding the relationship between arrhythmias and these complications in the acute and chronic stages following OHT is critical in improving patient prognosis, as arrhythmias may be the earliest or sole presentation. Finally, decentralised/denervated hearts represent a unique opportunity to investigate the underlying mechanisms of arrhythmias.

Keywords

Orthotopic heart transplantation, arrhythmias, bradyarrhythmia, sudden cardiac death, graft rejection, transplant vasculopathy

Disclosure: Authors have no conflicts of interest to declare.

Received: 8 July 2014 **Accepted:** 7 October 2014 **Citation:** *Arrhythmia & Electrophysiology Review*, 2014;**3**(3):149–55 **Access at:** www.AERjournal.com

Correspondence: Noel G Boyle, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 660, Los Angeles, CA 90095-1679, US.

E: NBoyle@mednet.ucla.edu

Support: Supported by grants from the French Federation of Cardiology (to Dr Hamon) and the NIH/National Heart Lung and Blood Institute R01HL084261 (to Dr Shivkumar).

Orthotopic heart transplantation (OHT) is the most effective long-term therapy for end-stage heart disease, with implanted left ventricular assist devices ('destination therapy') as an alternative for selected patients. The denervation of the transplanted heart with complete loss of autonomic nervous system modulation, the use of immunosuppressant drugs, as well as the risk of allograft rejection (AR) and vasculopathy, all change the incidence, prognosis and treatment of tachyarrhythmias and bradyarrhythmias, as well as the mechanisms of sudden cardiac death (SCD).

Arrhythmias post-OHT can be classified according to their underlying mechanisms (see *Table 1*). Tachyarrhythmias and bradyarrhythmias can come from the transplanted heart, be due to the surgery itself or result from AR or vasculopathy. In addition, bradyarrhythmias may be caused by drugs taken by the recipient patient before surgery. This review aims to present the most common causes of arrhythmias in OHT patients, and to highlight the importance of ruling out and treating AR and vasculopathy – transplant coronary artery disease (TCAD), which should always be the first concern. The causative mechanisms represent different risk factors, and overlap is possible, which may increase the occurrence of such arrhythmias.

With the increasing success of radiofrequency (RF) ablation techniques, it is important that cardiologists are familiar with tachycardias and bradycardias in this context, which may benefit from a multidisciplinary approach in the management of the patient starting with the underlying mechanisms.

Tachyarrhythmias

Supraventricular Tachycardia

The most common atrial arrhythmia in OHT patients is atrial flutter (AFL) followed by atrial fibrillation (AF) with respective incidences of 2.8 %¹ to 30.0 %² and 0.3 %¹ to 24.0 %.² The discrepancies mostly reflect the fact that those studies have variable follow-up periods and often small cohorts. After 1991, the year of the first report of bicaval OHT, this technique progressively supplanted the prior standard atrial anastomosis OHT. In a small cohort of 66 patients, Grant et al.³ found a significant decrease in atrial arrhythmias in the post-operative period among patients undergoing bicaval OHT (9.7 %) compared with those undergoing standard OHT (37.1 %). Maintenance of atrial conformation with better ventricular filling and a reduced tendency to mitral and tricuspid regurgitation may have contributed to this acute decrease.⁴ In stable OHT patients, only reentrant atrial tachycardia (AT) linked to surgical scars at atrial suture lines seem decreased with bicaval OHT, but not other ATs.⁵ The major limitation of such studies is that this group also represents the most recently treated patients, and other factors including advances in medical therapy may contribute to the findings.

The largest and most recent studies report a smaller incidence of supraventricular tachycardias (SVTs) due to improvements in graft preservation, surgical techniques resulting in neural decentralisation and isolation of the posterior left atrial wall in addition to advances in immunosuppressant therapy. Thus, post-operative OHT AF or AFL (POAF, POAFL) is not a common finding compared with other thoracic surgeries. Indeed, Khan et al.¹ first compared the incidence of AF, AFL

Table 1: Arrhythmias in Transplanted Hearts and Main Underlying Mechanisms

Tachyarrhythmia Mechanism	Examples
1 Coming from the transplanted heart	AVRT, AVNRT
2 Due to surgery	AFL, atrio-atrial reentrant tachycardia
3 Due to rejection or vasculopathy	Early AFL, AF and most late AF
Bradyarrhythmia Mechanism	Examples (SND>>AVB)
1 Coming from the transplanted heart	Older donors with pre-existing SND
2 Due to surgery	SAN artery injury, biatrial surgery, IT
3 Due to rejection or vasculopathy	Rejection involving sometimes HPS only
4 Recipient prior drug exposure	Amiodarone+++

AF = atrial fibrillation; AFL = atrial flutter; AV = atrioventricular; AVB = atrioventricular block; AVRT = atrioventricular reentrant tachycardia; AVNRT = atrioventricular nodal reentrant tachycardia; HPS = His-Purkinje system; IT = ischaemic time; SAN = sinoatrial nodal; SND = sinus node dysfunction.

and other SVTs in heart transplant versus matched low-risk coronary artery bypass graft (CABG) patients. They demonstrated that the OHT group had uncommon AT (0.3 % AF + 2.8 % AFL) when compared with CABG (25 % AF + 17 % AFL), and interestingly, 'other SVT' cases were not so different between two groups (1.3 versus 4.3 %, respectively). Dizon et al.⁶ compared the incidence of AF and AFL in heart transplant versus double-lung transplant and CABG surgery patients. Consistently, the OHT group had uncommon AT (4.6 % AF + 2.9 % AFL) when compared with the two other thoracic surgeries (18.9 % AF + 7.4 % AFL and 19.8 % AF + 3.8 % AFL, respectively). In a similar study, Noheria et al.⁷ also found that POAF occurred only in 6.5 % of OHT patients, and was much more frequent after maze (22.7 %) or CBAG (16.4 %) surgery. POAF is usually benign and thought to be secondary to the immediate post-operative inflammatory state.⁸ The two main factors that may contribute to the lower incidence of AT in OHT compared with other thoracic surgeries are autonomic denervation and the use of steroids in OHT.

The common underlying mechanisms, prognosis and therapeutic strategies for each arrhythmia are described below.

Atrial Fibrillation

Early and late AF incidences and mechanisms (association with graft rejection), are shown in Table 2. In addition to small cohorts and variable follow-up durations, the definition of AF itself played an important role, as some studies counted brief episodes (33 % <6 minutes), while others included only sustained episodes.² Moreover, the period used to link AF to acute rejection ranged from one week to one month.

These studies demonstrate that POAF (first month after surgery) is an uncommon finding (6 %), and is associated with AR in about one-third of patients. AF in this period was not associated with a poorer prognosis in OHT patients.

AF after the immediate post-operative period (after one month) was rare (4 %) but was associated with very poor outcomes. Indeed, almost no studies reported AF in stable OHT patients. AF in this context was mostly associated with AR in half of the cases and TCAD in almost one-quarter (and also diabetes).⁹ The remaining cases of AF in this context were linked to sepsis or multiple organ failure.

Pavri et al.² found that AF in OHT was associated with a three-fold increased risk of death (relative risk [RR] 3.15). Detailed analysis revealed that only late AF patients were affected and 100 % of them died. The reason for this is not clear, but it is likely that the more severe AR in this period, the cumulative effect of repeated AR episodes and TCAD may be determinant factors. In the absence of central autonomic factors, which increase dispersion of atrial refractoriness,¹⁰ and in the presence of pulmonary vein isolation, AF is more likely to be induced by a disease state of the myocardium (immune, ischaemic), or an abnormal neurohormonal milieu with an increased response to endogenous catecholamines¹¹ and adenosine¹² due to denervation. Acute changes caused by AR include oedema, lymphocytes infiltrate and myocardial necrosis; repeat episodes are associated with increased myocardial stiffness and fibrosis,^{13–15} which is likely to promote atrial heterogeneity and areas of slow conduction, facilitating AF.

Atrial Flutter

In the early post-operative period, AFL appeared to be even less common than AF (3 %) but the ratio AFL/AF (1/2) was much higher than after other thoracic surgeries (1/3–1/5)⁶ (see Table 3). Indeed, AR was more linked to POAFL than POAF (one every two versus one every three patients, respectively). A study by Ahmari et al.¹⁶ provided new insights, showing that acute rejection was associated with predominant increased pressure and size in the right rather than in the left atrium. The right ventricle is probably more affected by AR and, as with chronic lung diseases, is likely to increase the AFL/AF ratio in such circumstances. Interestingly, no study has shown a correlation between left ventricular ejection fraction (LVEF) and SVT occurring in the first month during acute AR. Only myocardial biopsies provide a diagnosis of AR, with the sensitivity depending on the number and site.

On the other hand, AFL after the first month post-OHT is slightly more frequent (7 %) than AF and has not clearly been linked to AR. Vaseghi

Clinical Perspective

- Atrial tachycardia (AT) is an uncommon finding after orthotopic heart transplantation (OHT) compared with other surgeries, and is highly associated with acute rejection.
- Atrial fibrillation (AF) is exceptionally rare in stable OHT patients, so late AF must lead physicians to rule out and treat acute rejection, transplant coronary artery disease (TCAD) or sepsis.
- Late and stable atrial flutter/AT are amenable to ablation, and good outcomes suggest the therapeutic strategy should not differ from non-OHT patients.
- Bradyarrhythmias post-OHT respond to sympathomimetics in 50 % of cases; permanent pacing is indicated for persistent symptomatic bradycardia.
- Most sudden cardiac death in OHT patients is a consequence of TCAD, with mainly asystolic presentation and almost never ventricular fibrillation in patients with moderately depressed or preserved left ventricular ejection fraction. Pending randomised trials, any evidence of bradycardia or conduction disease merits very careful patient evaluation and consideration for either a pacemaker or an implantable cardioverter defibrillator.

Table 2: Atrial Fibrillation Frequency and Significance in Transplanted Patients

Author	Year	patients	POAF	AR	Late AF	AR/TCAD	ΣAF	Total AR
Chang ⁹	2013	217			11.0 %	22.3 % AR 25.0 % TCAD 12.5 % sepsis		
Noheira ⁷	2013	155	6.5 %		0 %		6.5 %	
Dasari ¹⁹	2010	228	8.0 %		5.0 %		13.0 %	
Dizon ⁶	2009	174	2.9 %		1.7 %		4.6 %	62.5 %
Cohn ⁴⁶	2008	498	5.4 %	52.0 %				
Vaseghi ¹⁵	2008	657	4.0 %		3.0 %	80.0 % AR 15.0 % TCAD 5.0 % sepsis	7.0 %	34.8 % AR 6.5 % TCAD
Ahmari ¹⁶	2006	167			9.5 %	HR 2.3		
Khan ¹	2006	857					0.3 %	
Cui ¹⁷	2001	892	7.0 %	32.0 %	2.0 %	47.0 % AR 24.0 % TCAD	11.4 %	61.0 %
Grant ³	1995	66	10.6 %	28.6 %				
Pavri ²	1995	88	18.2 %		5.8 %		24.0 %	
TOTAL		3,999	6.2 %	37.5 %	4.0 %	46.0 % AR 21.0 % TCAD	7.2 %	53.0 %

AF = atrial fibrillation; AR = allograft rejection; HR = hazard ratio of AF when AR is present; POAF = post-operative atrial fibrillation; TCAD = transplant coronary artery disease; ΣAF = overall AF during follow-up.

Table 3: Atrial Flutter Frequency and Significance in Transplanted Patients

Author	Year	Patients	POAFL	AR	Late AFL	AR/TCAD	ΣAFL	Total AR
Chang ⁹	2013	217			18.4 %	27.3 % AR 40.0 % TCAD		
Noheira ⁷	2013	155	4.0 %		7.0 %		11.0 %	
Dasari ¹⁹	2010	228	3.0 %		4.0 %		7.0 %	
Dizon ⁶	2009	174						
Cohn ⁴⁶	2008	498	1.6 %					
Vaseghi ¹⁵	2008	657	2.4 %				9.1 %	28.3 % AR 3.3 % TCAD
Ahmari ¹⁶	2006	167			15.0 %	HR 2.96		
Khan ¹	2006	857				No association	2.8 %	No
Cui ¹⁷	2001	892	2.0 %	50 %	4.6 %	78.0 % AR 51.0 % TCAD	11.7 %	83.0 %
Grant ³	1995	66	3.0 %	50 %				
Pavri ²	1995	88	21.6 %		7.9 %		29.5 %	
Jacquet ⁴⁷	1990	25	8.0 %	50 %				
TOTAL		4,024	2.9 %	50 %	7.4 %	Contradictory results	8.6 %	62.8 %

AFL = atrial flutter; AR = allograft rejection; HR = hazard ratio of AFL when AR is present; POAFL = post-operative atrial flutter; TCAD = transplant coronary artery disease; ΣAFL = overall AFL during follow-up.

et al.⁵ and Chang et al.⁹ reported that 28 % of overall and late AFL, respectively, were associated with AR, but no comparison was done with sinus rhythm patients. Khan et al.¹ did not find any association with rejection, but the Cui et al.¹⁷ study yielded a clear link when mild rejection (Grade 1–2 of the International Society for Heart and Lung Transplantation classification¹⁸) was also considered. In contrast to AF, no study has shown increased mortality in OHT patients experiencing AFL. In the Pavri et al.² study a nonsignificant trend was weakened further by the fact that 78 % of those who died also had an episode of AF. Dasari et al.¹⁹ showed a significant increase in mortality associated with late arrhythmias only, but this analysis combined AF and AFL. Finally, Vaseghi et al.⁵ reported, in their stable (no AR) OHT cohort with SVT refractory to medical therapy, that 58 % were AFL. This was consistent with other studies^{20,21} where most stable OHT patients referred for ablation had cavotricuspid isthmus flutter and all were ablated successfully without any recurrence.

Other Supraventricular Tachycardias

The following arrhythmias have been described only in stable OHT patients referred for electrophysiological testing and ablation,^{5,20,21} thus allowing for a precise diagnosis; however, the possibility that AR or TCAD may be triggers in some patients cannot be excluded.

After isthmus-dependent AFL, the most common reentrant arrhythmias are:

- Atrial macro-reentrant tachycardia (see *Figure 1*) – mostly occurring in the upper right atrium, around the native and donor suture line. The surgical scars at atrial suture lines can create areas of slower conduction, which were successfully targeted in all ablations. Such arrhythmias are typically the second group described, due to surgery (see *Table 1*), and they have promoted in part the development of bicaval anastomosis.
- Recipient-to-donor atrial conduction tachycardia also usually involved the right atrial anastomosis. In these cases, ablations were successfully performed at the site of the earliest donor atrial activation on the suture line and the recipient atria was not targeted. Further, recipient tachycardia or atrial rhythm with exit block to the donor atrium can challenge physicians with complex electrocardiograms (ECGs) showing dual atrial tachycardia,²² pseudo-atrioventricular (AV) block²³ or a pseudo-atrial tachycardia with atrial waves of two different morphologies (one from the donor and one from the recipient).
- AV and AV nodal reentrant tachycardia with successful ablation of the accessory or slow atrioventricular pathways. We classified these (see *Table 1*) as arrhythmias that come with the transplanted heart, even if the donor never experienced any tachycardias; changes in autonomic tone affecting the substrate are likely to be the mechanism of tachycardias in the recipient patient.

Figure 1: Left Macro-reentrant Scar-related Atrial Tachycardia

A: Surface ECG showing atrial tachycardia at a rate of 150 beats/minute; B: Activation map demonstrates the tachycardia using an isthmus in the left atrium, involving the donor, but not native left atrium (grey). C: Fluoroscopic left anterior oblique view during mapping after transseptal catheterisation. ABL = ablation catheter; CS = coronary sinus; LA and RA = left and right atrium. Reproduced with permission from Vaseghi, et al. 2008⁵

Figure 2: Management of Atrial Arrhythmias after Orthotopic Heart Transplantation

**Or as soon as possible. AF = atrial fibrillation; CAV = cardiac allograft vasculopathy; EMB = endomyocardial biopsy; ID = infectious disease; RF = radiofrequency ablation. Although rejection may underlie some cases of early AF, late AF or flutter is associated with rejection, significant graft vasculopathy, or secondary causes. Reproduced with permission from Thajudeen, et al. 2012.⁴⁸*

Evaluation and Treatment

In the Post-operative Period (First Month)

Symptomatic treatment with rate control (beta-blockers) and cardioversion as needed is preferred during this period. In all cases, optimisation of electrolyte status and weaning inotropes will benefit the patient. It is important to diagnose and treat AR and, in the case of persistent AF or AFL, repeating endomyocardial multisite biopsy may be helpful if the previous

biopsy was negative. When anticoagulant therapy is needed, warfarin and dabigatran should be avoided because of the interaction with cyclosporin. Rivaroxaban and apixaban are probably the best choices in this setting. Use of antiarrhythmic drugs and calcium channel blockers is discouraged not only because of drug–drug interactions, but also because of the risk of severe bradycardia requiring pacing. Amiodarone should be avoided because of its prolonged effect, which may result in prolonged interaction needing monitoring of immunosuppressant levels, and prolonged sinus bradycardia requiring pacemaker implantation before patient discharge. When truly essential, class I antiarrhythmic drugs are most commonly used as TCAD is not expected in the early stage. It is important to note that in the Vaseghi et al.⁶ study none of the patients with POAF or POAFL had recurrence after cardioversion and drug discontinuation during follow-up, unless associated with repeat AR episodes or severe TCAD. Thus, without evidence of an increased risk of developing paroxysmal or persistent AF, antiarrhythmic drugs should be discontinued as soon as possible and anticoagulation discontinued one month later.

In the Late Period (After the First Month)

All patients with atrial arrhythmias without significant contraindications should receive anticoagulation therapy, irrespective of their CHADS₂/CHA₂DS₂-VASc score. In the study by Chang et al., in which patients received anticoagulation based on CHADS₂ score, the group with atrial arrhythmias suffered more nonfatal cerebrovascular events compared with those in sinus rhythm (13.7 versus 3.6 %).⁹ Both AF and AFL patients should first be screened for AR and TCAD, with appropriate treatment. In the case of negative results, AF should be closely monitored with repeated biopsy and screened for sepsis. Antiarrhythmic drugs should be managed very carefully especially when patients have TCAD, and patients with stable paroxysmal or persistent AT should be considered for catheter ablation. In patients with persistent AT, anticoagulants should be discontinued one month after documented successful ablation, given the excellent follow-up results in these studies.^{5,20,21}

Ventricular Tachycardia

Chang et al.⁹ analysed outcomes in patients experiencing ventricular tachycardia (VT; non-sustained and sustained) and have shown that among all arrhythmias this group had the poorest prognosis (89 % mortality at 83 months). The mean ejection fraction was normal and no patient died from a cardiovascular death; half of the deaths were associated with infection, one-third with AR and one-third with TCAD (there were some cases with both AR and TCAD). A case report²⁴ described sustained bidirectional VT occurring during acute ischaemia in a patient with severe TCAD and ejection fraction (EF) of 40 %, requiring amiodarone, lidocaine and cardioversion. No VT was inducible with programmed stimulation and the patient underwent implantable cardioverter defibrillator (ICD) implantation but never had any appropriate therapy during follow-up. Thus, VT episodes should lead to careful evaluation of the underlying condition.

Bradyarrhythmias

Bradyarrhythmias occur in 8–23 % of patients after OHT depending on the case series. In most cases sinus node dysfunction is the main complication but AV block may also occur. The aetiology of sinus node dysfunction is variable and the transplantation technique itself can have a major influence. In the 1995 study of Grant et al.,³ 66 patients survived more than 30 days, of which 35 underwent the biatrial anastomotic technique and 31 the bicaval technique. Three patients from the biatrial surgery group (8.6 %) received a permanent pacemaker while none from the bicaval technique group did. In a

large United Network for Organ Sharing (UNOS) registry of almost 36,000 transplant patients reported in 2010, Cantillon et al.²⁵ found that the bicaval technique was strongly protective against a need for a pacemaker (odds ratio, 0.33), and overall 10.9 % of the population required a pacemaker implant.

Transplanted heart autonomic changes with sympathetic and parasympathetic decentralisation/denervation can also lead to decreased sinus node automaticity, resulting in increased baseline and decreased maximum heart rate during exercise.²⁶ Prolonged donor heart ischaemia time can predispose to conduction system injury in the post-operative period,²³ while rejection can involve the cardiac conduction system and lead to bradyarrhythmias.²⁷ Abnormalities of sinoatrial (SA) nodal artery may also influence sinus node dysfunction in patients who undergo OHT. One study performed routine coronary angiography in the first six weeks after the OHT and found that 30 % of SA nodal artery anomalies were in patients with implanted pacemakers and 6 % in the control group (without permanent pacemaker). In the same study, no correlation was found between graft ischaemia time and bradycardia.²³ Sinus node dysfunction was described as sinus bradycardia in 17 %, sinus arrest in 27 % and junctional rhythm in 47 % of patients, while 63 % of the patients were asymptomatic and 73 % presented in the early post-operative period.

AV node dysfunction has similar multiple possible aetiologies in patients after OHT. It is most common in the late period after OHT. One study analysed the incidence of AV block among 1,047 patients finding first-degree AV block in 8.3 %, Mobitz I in 0.6 %, Mobitz II in 0.1 % and complete AV block in 1.8 %.²⁸ Pre-operative use of amiodarone in the recipient patient may also result in post-transplant bradycardia. MacDonald et al. reported that these patients required longer periods of atrial pacing immediately post-transplant (mean seven versus three days), but that there was no effect of prior amiodarone therapy on inotropic function or clinical outcome.²⁹

Evaluation and Treatment

In the perioperative period bradycardia may be managed with temporary pacing.²⁸ However, in up to 50 % of cases, sympathomimetics such as terbutaline or isoproterenol may be used to maintain the heart rate over 90 beats per minute, while waiting for recovery of sinus node function.³⁰ In the case of sinus node dysfunction after heart transplantation, the current European Society of Cardiology (ESC) guidelines (2013) state that “a period of clinical observation from five days up to some weeks is indicated in order to assess if the rhythm disturbance resolves” (Class I recommendation, level of evidence C).³¹ Prompt permanent pacemaker implantation is indicated for symptomatic bradycardia and persistent second- or third-degree AV block. As previously noted, overall 10.9 % of patients in the UNOS database required pacemaker implantation.²⁵ In cases of sustained bradycardia, consider endomyocardial biopsy to exclude the possibility of rejection.

In patients with late onset symptomatic bradycardia, rejection and TCAD should be excluded. In one study six of 18 patients underwent pacemaker implantation (three with sinus node dysfunction and three with AV block) and only two of them became dependent during follow-up. This study also found that the mechanism for late onset bradyarrhythmias is unclear, but 30 % of cases occurred in patients with TCAD, while acute rejection was rarely seen (5 %).⁹ TCAD was shown as a main reason for SCD, presenting with asystole and bradycardia.³² The optimal time for pacemaker implantation and prophylactic pacemaker

Figure 3: Management of Post-operative Bradycardia

EMB = endomyocardial biopsy. Reproduced with permission from Thajudeen, et al. 2012.³³

implantation for bradycardia during the rejection period is not well defined. Permanent pacing is indicated for OHT patients with persistent, inappropriate or symptomatic bradycardia not expected to resolve, with a class I recommendation, level of evidence C, according to the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guidelines.³³

Sudden Cardiac Death

Insights into SCD in OHT patients come from the Vaseghi et al. retrospective study³⁴ of 628 patients, with 194 deaths, including 116 with a determined cause. In this cohort, one-third died of SCD, and interestingly, the terminal rhythm was asystole in 34 %, followed by pulseless electrical activity (PEA) in 20 % and ventricular fibrillation (VF) in only 10 % (unknown in 36 %). Almost two-thirds of SCDs were induced by acute ischaemia, and this subgroup yielded even more unexpected data since 50 % died from asystole, 44 % from PEA and only 6 % (one patient) from VF. In contrast, SCD in the general population is also associated with the same proportion of ischaemic heart disease (two-thirds), but VF is the most common mechanism occurring in up to two-thirds.³⁵ Results in this OHT cohort could be prejudiced since it is difficult to rule out that VF degenerating to PEA or asystole occurred first, with PEA/asystole then recorded and counted as the initial rhythm. Nonetheless, among 11 patients implanted with ICDs for severe TCAD with depressed LVEF, out-of-hospital cardiac arrest, syncope or recurrent non-sustained ventricular tachycardia (NSVT), only one experienced an appropriate shock (which was possibly related to recurrent NSVT with an older defibrillator), while two patients received multiple inappropriate therapies (six shocks, five anti-tachycardia pacing).

Non-SCD patients in this cohort represented a very distinct profile as they died shortly after OHT (16 versus 38 months for SCD) and mostly from sepsis (43 versus 0 %), but almost never from ischaemia (4 %), and similarly from AR (13 versus 15 %). Again, the first documented rhythm was asystole (73 %).

As surgical techniques and immunosuppressive regimens have been refined, short-term mortality caused by sepsis has been replaced by increasing morbidity and mortality caused by TCAD. Prevention of SCD in this population has become a major concern in OHT care. The benefits of ICD implantation in OHT patients are limited and controversial. Indeed, patients who died from SCD had similar LVEF (48 %) to patients who died from non-SCD, which is not surprising considering that most patients died from asystole and not from VF. This is consistent with the cohort study of Leonelli et al.³⁶ involving 89 patients, in which all five who died from SCD belonged to the group of patients with ECG evidence of progressive conduction system damage during follow-up (i.e. a new hemiblock or complete bundle branch block), of which two were directly related to bradycardia. All five patients had TCAD and the group experienced a mild deterioration of LVEF (62–55 %) during follow-up. The authors proposed that TCAD (or AR), which is known to affect the myocardium could also directly injure the conduction system and increase risk of SCD from bradycardia. On the other hand, Ptaszek et al.³⁷ reported, in a cohort of 10 patients implanted 15 years after OHT, including five with severe decrease in LV function, that three of them had appropriate ICD therapy during follow-up. It is possible that reinnervation long after the surgery may have induced a higher susceptibility to ventricular arrhythmias with beneficial effect from ICD implant.

Improvements in the prevention and treatment of TCAD should be the cornerstone for decreasing mortality, and prospective studies are needed to enhance screening and choice of device. OHT patients with sinus node dysfunction should be implanted with a dual chamber pacemaker because of additional risk of asystole associated with TCAD. Furthermore, even TCAD patients who have a borderline indication for pacing such as paroxysmal, asymptomatic bradycardia or progressive conduction disease may benefit from pacemaker implantation, as procedural and infection risks probably do not counterbalance the risk of asystole and SCD. At least TCAD patients should undergo a careful assessment of the conduction system integrity by repeat ECG, Holter monitoring or electrophysiological studies leading to a multidisciplinary improved estimation of SCD risk. Finally, the use and benefit of beta-blocker therapy in TCAD patients should be carefully assessed in patients without pacemakers or ICDs because of asystole risk.

Interesting Pathophysiological Findings Associated with Arrhythmias in Orthotopic Heart Transplantation

OHT provides a unique model of the decentralised/denervated heart and reveals insights into the mechanism of arrhythmias. While one may assume that re-innervation occurs after OHT, Vaseghi et al.⁵ reported highly depressed heart rate variability parameters, even years after the graft surgery, which was consistent with previous studies.^{38,39} Specific findings are:

- The lower rate of peri-operative AF after OHT compared with other thoracic surgeries, with predominantly absence of AF in stable OHT patients, strongly supports both the autonomic and the pulmonary vein trigger hypothesis for genesis of AF. Moreover, AF episodes occurring long after transplantation are only associated with rejection or ischaemia, which alter the normal atrial substrate.¹⁷ As expected, during the acute post-operative state, only denervation is likely to decrease AF in OHT patients, as suggested by the higher rates after maze⁷ or double-lung transplantation⁶ both of which require pulmonary vein isolation.
- In the stable OHT cohort of Vaseghi et al.,⁵ among patients presenting with SVT referred for ablation, only 13 % were asymptomatic while 58 % were able to feel palpitations. Beyond a possible referral bias, this interesting finding supports the idea that palpitations may reflect chest wall rather than cardiac sensitivity.⁴⁰
- In the same study, one of the 14 patients with AFL was associated with a tachycardia induced cardiomyopathy, which fully reversed after ablation. Hence the autonomic nervous system does not appear to be critical in the generation of tachycardia-mediated cardiomyopathy.
- In a second study by Vaseghi et al.³⁴ VF as the mechanism of SCD was rare, even during acute ischaemia. Such findings highlight the critical role of the autonomic nervous system in the genesis and maintenance of malignant ventricular arrhythmias, particularly during ischaemia, which has been demonstrated for decades to induce a sympathetic reflex.⁴¹ Sympathetic hyperinnervation, which follows the denervation of scarred myocardium leads to a heterogeneous response to sympathetic stimulation causing an increased incidence of VT/VF.^{42,43} Furthermore, cervicothoracic sympathectomy, particularly bilateral, can have a significant antiarrhythmic effect.^{44,45} The decreased sympathetic reflex in the setting of ischaemia involving conduction system could also be a factor in asystole by decreasing the likelihood of an escape rhythm emerging. ■

- Khan M, Kalahasti V, Rajagopal V, et al. Incidence of atrial fibrillation in heart transplant patients: long-term follow-up. *J Cardiovasc Electrophysiol* 2006;**17**(8):827–31.
- Pavri BB, O'Nunain SS, Newell JB, et al. Prevalence and prognostic significance of atrial arrhythmias after orthotopic cardiac transplantation. *J Am Coll Cardiol* 1995;**25**(7):1673–80.
- Grant SC, Khan MA, Faragher EB, et al. Atrial arrhythmias and pacing after orthotopic heart transplantation: bicaval versus standard atrial anastomosis. *Br Heart J* 1995;**74**(2):149–53.
- Kendall SW, Ciulli F, Biocina B, et al. Atrioventricular orthotopic heart transplantation: a prospective randomised clinical trial in 60 consecutive patients. *Transplant Proc* 1993;**25**(1 Pt 2):1172–3.
- Vaseghi M, Boyle NG, Kedia R, et al. Supraventricular tachycardia after orthotopic cardiac transplantation. *J Am Coll Cardiol* 2008;**51**(23):2241–9.
- Dizon JM, Chen K, Bacchetta M, et al. A comparison of atrial arrhythmias after heart or double-lung transplantation at a single center: insights into the mechanism of post-operative atrial fibrillation. *J Am Coll Cardiol* 2009;**54**(22):2043–8.
- Noheria A, Patel SM, Mirzoyev S, et al. Decreased postoperative atrial fibrillation following cardiac transplantation: the significance of autonomic denervation. *Pacing Clin Electrophysiol* 2013;**36**(6):741–7.
- Meisel WH, Rawl JD, Stevenson WG. Atrial fibrillation after cardiac surgery. *Ann Intern Med* 2001;**135**(12):1061–73.
- Chang HY, Lo LW, Feng AN, et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. *Transplant Proc* 2013;**45**(1):369–75.
- Euler DE, Scanlon PJ. Acetylcholine release by a stimulus train lowers atrial fibrillation threshold. *Am J Physiol* 1987;**253**(4 Pt 2):H863–8.
- Yusuf S, Theodoropoulos S, Mathias CJ, et al. Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. *Circulation* 1987;**75**(4):696–704.
- Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. *Circulation* 1990;**81**(3):821–8.
- Stengel S, Allemann Y, Zimmerli M, et al. Doppler tissue imaging for assessing left ventricular diastolic dysfunction in heart transplant rejection. *Heart* 2001;**86**(4):432–7.
- Valantine HA, Appleton CP, Hatle LK, et al. A hemodynamic and Doppler echocardiographic study of ventricular function in long-term cardiac allograft recipients. Etiology and prognosis of restrictive-constrictive physiology. *Circulation* 1989;**79**(1):66–75.
- Puleo JA, Aranda JM, Weston MW, et al. Noninvasive detection of allograft rejection in heart transplant recipients by use of Doppler tissue imaging. *J Heart Lung Transplant* 1998;**17**(2):176–84.
- Ahmari SA, Bunch TJ, Chandra A, et al. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter. *J Heart Lung Transplant* 2006;**25**(1):53–60.
- Cui G, Tung T, Kobashigawa J, et al. Increased incidence of atrial flutter associated with the rejection of heart transplantation. *Am J Cardiol* 2001;**88**(3):280–4.
- Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. *J Heart Transplant* 1990;**9**(6):587–93.
- Dasari TW, Pavlovic-Surjanec B, Patel N, et al. Incidence, risk factors, and clinical outcomes of atrial fibrillation and atrial flutter after heart transplantation. *Am J Cardiol* 2010;**106**(5):737–41.
- Nof E, Stevenson WG, Epstein LM, et al. Catheter ablation of atrial arrhythmias after cardiac transplantation: findings at EP study utility of 3-D mapping and outcomes. *J Cardiovasc Electrophysiol* 2013;**24**(5):498–502.
- Elsik M, Teh A, Ling LH, et al. Supraventricular arrhythmias late after orthotopic cardiac transplantation: electrocardiographic and electrophysiological characterization and radiofrequency ablation. *Europace* 2012;**14**(10):1498–505.
- Nevzorov R, Ben-Gal T, Strasberg B, Haim M. Atrial flutter in a post-transplant recipient. *Isr Med Assoc J* 2012;**14**(7):448–9.
- Dibiase A, Tse TM, Schnittger I, et al. Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakers. *Am J Cardiol* 1991;**67**(16):1385–9.
- Bhavnani SP, Clyne CA. Bidirectional ventricular tachycardia due to coronary allograft vasculopathy: a unique presentation. *Ann Noninvasive Electrocardiol* 2012;**17**(4):405–8.
- Cantillon DJ, Tarakji KG, Hu T, et al. Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: analysis of

- the UNOS/OPTN cardiac transplant database. *Heart Rhythm* 2010;**7**(11):1567–71.
26. Banner NR, Patel N, Cox AP, et al. Altered sympathoadrenal response to dynamic exercise in cardiac transplant recipients. *Cardiovasc Res* 1989;**23**(11):965–72.
 27. Cooper MM, Smith CR, Rose EA, et al. Permanent pacing following cardiac transplantation. *J Thorac Cardiovasc Surg* 1992;**104**(3):812–6.
 28. Cui G, Kobashigawa J, Margarian A, Sen L. Cause of atrioventricular block in patients after heart transplantation. *Transplantation* 2003;**76**(1):137–42.
 29. Macdonald P, Hackworthy R, Keogh A, et al. The effect of chronic amiodarone therapy before transplantation on early cardiac allograft function. *J Heart Lung Transplant* 1991;**10**(5 Pt 1):743–8; discussion 748–9.
 30. Redmond JM, Zehr KJ, Gillinov MA, et al. Use of theophylline for treatment of prolonged sinus node dysfunction in human orthotopic heart transplantation. *J Heart Lung Transplant* 1993;**12**(1 Pt 1):133–8; discussion 138–9.
 31. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Europace* 2013;**15**(8):1070–118.
 32. Grinstead WC, Smart FW, Pratt CM, et al. Sudden death caused by bradycardia and asystole in a heart transplant patient with coronary arteriopathy. *J Heart Lung Transplant* 1991;**10**(6):931–6.
 33. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation* 2008;**117**(21):e350–408.
 34. Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms of death after orthotopic heart transplantation. *Heart Rhythm* 2009;**6**(4):503–9.
 35. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. *Clin Cardiol* 2005;**28**(11 Suppl 1):13–11.
 36. Leonelli FM, Dunn JK, Young JB, Pacifico A. Natural history, determinants, and clinical relevance of conduction abnormalities following orthotopic heart transplantation. *Am J Cardiol* 1996;**77**(1):47–51.
 37. Ptasek LM, Wang PJ, Hunt SA, et al. Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation. *Heart Rhythm* 2005;**2**(9):931–3.
 38. Stevenson LW, Sietsema K, Tillisch JH, et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. *Circulation* 1990;**81**(1):78–85.
 39. Quigg RJ, Rocco MB, Gauthier DF, et al. Mechanism of the attenuated peak heart rate response to exercise after orthotopic cardiac transplantation. *J Am Coll Cardiol* 1989;**14**(2):338–44.
 40. Khalsa SS, Rudrauf D, Feinstein JS, Tranel D. The pathways of interoceptive awareness. *Nat Neurosci* 2009;**12**(12):1494–6.
 41. Brown AM, Malliani A. Spinal sympathetic reflexes initiated by coronary receptors. *J Physiol* 1971;**212**(3):685–705.
 42. Cao JM, Fishbein MC, Han JB, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. *Circulation* 2000;**101**(16):1960–9.
 43. Chen PS, Chen LS, Cao JM, et al. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. *Cardiovasc Res* 2001;**50**(2):409–16.
 44. Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. *Heart Rhythm* 2014;**11**(3):360–6.
 45. Bourke T, Vaseghi M, Michowitz Y, et al. Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. *Circulation* 2010;**121**(21):2255–62.
 46. Cohn WE, Gregoric ID, Radovancevic B, et al. Atrial fibrillation after cardiac transplantation: experience in 498 consecutive cases. *Ann Thorac Surg* 2008;**85**(1):56–8.
 47. Jacquet L, Ziady G, Stein K, et al. Cardiac rhythm disturbances early after orthotopic heart transplantation: prevalence and clinical importance of the observed abnormalities. *J Am Coll Cardiol* 1990;**16**(4):832–7.
 48. Thajudeen A, Stecker EC, Shehata M, et al. Arrhythmias after heart transplantation: mechanisms and management. *J Am Heart Assoc* 2012;**1**:e001461.